Patient Guide: A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 28 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT04721977
Status: ACTIVE_NOT_RECRUITING
Condition: Breast Cancer
Phase: PHASE2

Find a Study Location Near You

This study is available at 28 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Nagoya, Aichi
  • Nagoya, Aichi
  • Kashiwa, Chiba
  • • And 25 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily